Initial U.S. Approval: 2020
MenQuadfi is a vaccine indicated for active immunization for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y.
Guillain-Barré syndrome (GBS) has been reported in temporal relationship following administration of another U.S.-licensed meningococcal quadrivalent polysaccharide conjugate vaccine.
Children 2 through 9 years of age
SAEs [Serious Adverse Events] occurred at a rate of 1.4%
Adolescents 10 through 17 years of age
SAEs occurred at a rate of 0.8%
Adults 18 through 55 years of age
SAEs occurred at a rate of 1.6%
Adults 56 years of age and older
SAEs occurred at a rate of 3.3%
MenQuadfi is a sterile liquid vaccine administered by intramuscular injection that contains Neisseria meningitidis serogroup A, C, W, and Y capsular polysaccharide antigens that are individually conjugated to tetanus toxoid protein.
Each 0.5 mL dose of vaccine contains 10 microgram each of meningococcal A, C, W, and Y polysaccharide antigens conjugated to approximately 55 micrograms tetanus toxoid protein carrier; 3.35 mg sodium chloride (0.67%), and 1.23 mg sodium acetate (30 mM).
MenQuadfi has not been evaluated for carcinogenic or mutagenic potential or for impairment of male fertility.